ChongQing Zhengchuan Pharmaceutical Packaging Co Ltd

603976.CG▼

Zhengchuan Shares' 2026 Interim Report Shows Net Profit Down 12.79% Year-on-Year

Zhengchuan Shares released its 2026 interim report. Total operating revenue was 381 million yuan, and net profit attributable to the parent company was 12.2866 million yuan, down 12.79% from the same period last year. Net cash inflow from operating activities was 79.3259 million yuan. The asset-liability ratio was 37.64%, gross margin was 17.35%, return on equity was 1.03%, and diluted earnings per share was 0.08 yuan. The company had 21,600 shareholders, and the top ten shareholders held 71.87% of total share capital.

603976.CG ▼

Jiemian·19dRead more →

603976.CG▲3

Zhengchuan Shares Reports Steady First-Half Revenue Growth, Continues Advancing Premium Product Mix

Zhengchuan Shares released its 2026 interim report on the evening of August 28. During the reporting period, the company achieved operating revenue of 381 million yuan, up 17.58 percent year on year. Net profit attributable to the parent company was 12.2866 million yuan, down 12.79 percent year on year. Net cash flow from operating activities was 79.3259 million yuan, up 33.63 percent year on year. The company said that in the first half it actively stepped up market development, with both product sales volume and operating revenue scale achieving year-on-year growth. Facing a complex and severe external environment and the pains of industry transformation, the company consolidated its core business in traditional chemical pharmaceutical packaging while focusing on three emerging tracks: innovative drug supporting packaging, premium medical aesthetics packaging, and overseas international trade. The company seized industry opportunities from the commercialization ramp-up of innovative drugs, the expansion of the biologics market, and the rapid growth of the medical aesthetics injectables market. It continued to advance a more premium and differentiated product mix, with a key push into high-tech, high-value-added premium pharmaceutical glass products such as prefillable syringes, cartridge bottles, and ready-to-use molded vials. In the traditional business segment, market demand in the oral liquid pharmaceutical packaging materials sector remained steady, supply and demand for chemical pharmaceutical glass tubing continued to improve, and product volumes and prices gradually recovered. In the premium business segment, the company has completed product sampling, process validation, and small-batch supply for multiple well-known enterprises. In the medical aesthetics packaging segment, the company focused on mid-to-high-end, high-value-added product positioning, with operating results gradually being released. In the overseas business segment, the export share of high-value-added products steadily increased.

603976.CG ▲

证券时报·21dRead more →

603976.CG▼

Two executives at Zhengchuan Shares plan to reduce holdings by no more than 99,000 shares combined

Zhengchuan Shares announced that director and deputy general manager Xiao Qing plans to reduce his holdings by no more than 55,000 shares, representing 0.0320% of the company's total share capital, through centralized bidding between September 7 and December 6, 2026. Director and deputy general manager Jiang Fengan plans to reduce his holdings by no more than 44,000 shares, representing 0.0256% of the total share capital. The two executives plan to reduce their holdings by no more than 99,000 shares in total. In the first quarter of 2026, Zhengchuan Shares achieved revenue of 209 million yuan and net profit attributable to the parent company of 6.83 million yuan.

603976.CG ▼

财中社·36dRead more →